Media coverage

LaBiotech – French Biotech Raises €40M to Fight Hepatitis B and NASH

https://labiotech.eu/enyo-pharma-hepatitis-nas

Published on 05/06/2018

BioCentury – ENYO aims for Phase II HBV, NASH trials with €40m round

https://www.biocentury.com/bc-extra/financial-news/2018-06-04/enyo-aims-phase-ii-hbv-nash-trials-%E2%82%AC40m-round

Published on 05/06/2018

Le Journal des Entreprises – Levée de fonds record de 40 millions d’euros pour Enyo Pharma

https://www.lejournaldesentreprises.com/lyon-saint-etienne-grenoble/article/levee-de-fonds-record-de-40-millions-deuros-pour-enyo-pharma-123561

Published on 05/06/2018

Les Echos – Enyo Pharma mobilise 40 millions contre l’hépatite B et la NASH

https://www.lesechos.fr/pme-regions/innovateurs/0301751138430-enyo-pharma-mobilise-40-millions-contre-lhepatite-b-et-la-nash-2181141.php

Published on 05/06/2018

Fierce Biotech – Enyo Pharma raises $47M to bring hepatitis B, NASH drug to phase 2

https://www.fiercebiotech.com/biotech/enyo-raises-47m-to-bring-hep-b-nash-drug-to-phase-2

Published on 05/06/2018

News

Latest Press Release

ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome.
ENYO Pharma announ...

> Read more